Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Mimbane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.47 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mimbane SCHEMBL29658183 | 1.00 | SLC6A4 (0.47) | SLC6A4CYP1A2CYP2D6ADRA1AMCHR1 | |
| Mimbane SCHEMBL488924 | 0.99 | SLC6A4 (0.48) | SLC6A4CYP1A2CYP2D6ADRA1AMCHR1 | |
| SCHEMBL3857346 | 0.80 | MCHR1 (0.52) | SLC6A4CYP1A2CYP2D6ADRA1AMCHR1 | |
| SCHEMBL3858428 | 0.78 | MCHR1 (0.52) | SLC6A4CYP1A2CYP2D6ADRA1AMCHR1 | |
| SCHEMBL3867340 | 0.77 | SLC6A4 (0.62) | SLC6A4CYP1A2CYP2D6ADRA1A | |
| SCHEMBL6672112 | 0.76 | SLC6A4 (0.44) | SLC6A4CYP1A2CYP2D6MCHR1MEN1 | |
| SCHEMBL3354675 | 0.73 | ADRA2A (0.66) | CYP1A2CYP2D6ADRA1AMEN1KMT2A | |
| SCHEMBL1538791 | 0.71 | CHRNA7 (0.62) | CYP1A2CYP2D6ADRA1AMEN1KMT2A | |
| SCHEMBL21307810 | 0.71 | CHRNA7 (0.62) | CYP1A2CYP2D6ADRA1AMEN1KMT2A | |
| SCHEMBL29376699 | 0.71 | CHRNA7 (0.62) | CYP1A2CYP2D6ADRA1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 846 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240200072-A1 | Allogeneic Cartilage Regeneration | Tarachon, LLC (US) | 2024-06-20 | — | — | US | claimed |
| US-9566349-B2 | Intestinal peptide targeting ligands | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-02-14 | — | — | US | claimed |
| US-20160022820-A1 | TRANSDERMAL DELIVERY SYSTEM | ACRUX DDS PTY LTD. (AU) | 2016-01-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20080014272-A1 | Compositions and Methods for Treatment of Chronic Pain Conditions | DOV PHARMACEUTICAL, INC. | 2008-01-17 | — | — | US | claimed |
| WO-2008008474-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC PAIN CONDITIONS | DOV PHARMACEUTICAL, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| EP-1807071-A4 | ANTIPYRETIC COMPOSITIONS AND METHODS | DOV PHARMACEUTICAL INC (US) | 2008-01-09 | — | — | EP | claimed |
| EP-1807071-A2 | ANTIPYRETIC COMPOSITIONS AND METHODS | DOV Pharmaceutical Inc. (US) | 2007-07-18 | — | — | EP | claimed |
| US-20060100263-A1 | Antipyretic compositions and methods | DOV PHARMACEUTICAL, INC. | 2006-05-11 | — | — | US | claimed |
| WO-2006050520-A2 | ANTIPYRETIC COMPOSITIONS AND METHODS | DOV PHARMACEUTICAL, INC. (US) | 2006-05-11 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-3958767-B1 | DEVICES FOR DELIVERING THERAPEUTIC MATERIALS TO THE INTERVERTEBRAL DISC | WARSAW ORTHOPEDIC INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4719353-A1 | REVERSIBLE SURFACTANT AND MULTIFUNCTIONAL DRUG DELIVERY SYSTEMS BASED THEREON | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-04-08 | — | — | EP | disclosed |
| US-12582455-B2 | Bone material dispensing device | WARSAW ORTHOPEDIC, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-4440777-A | ANTIINFLAMMATORY AGENTS; ANESTHETICS; ADRENERGIC BLOCKING AGENTS; COSMETICS | MERCK & CO., INC. (US) | 1984-04-03 | — | — | US | disclosed |
| EP-0069385-A2 | Use of eucalyptol for enhancing skin permeation of bioaffecting agents | MERCK & CO. INC. (US) | 1983-01-12 | — | — | EP | disclosed |
| EP-0036138-A2 | Composition of matter for topical application comprising a bio-affecting agent and N,N-diethyl-m-toluamide | MERCK & CO. INC. (US) | 1981-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022820-A1 | TRANSDERMAL DELIVERY SYSTEM | S100A10, MMP20, TLR6 | SLC6A4 217/4885ADRA1A 2060/4885CYP1A2 595/4885 |
| US-20060100263-A1 | Antipyretic compositions and methods | GABRE, HTR5A, TPH2 | SLC6A4 673/4885ADRA1A 870/4885CYP1A2 335/4885 |
| US-12582455-B2 | Bone material dispensing device | BMP2, BMP4, BMP1 | SLC6A4 976/4885ADRA1A 4595/4885CYP1A2 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.